TILT Holdings Reports First Quarter 2025 Results
La società sta attuando una trasformazione strategica per diventare un'azienda focalizzata su Jupiter, dismettendo le attività legate alla coltivazione. Tra gli sviluppi chiave vi è la firma di un accordo da 2 milioni di dollari per la vendita di due dispensari nel Massachusetts e l'ottenimento della certificazione UE per dispositivi medici per il vaporizzatore QMID di Jupiter. TILT sta spostando la produzione di Jupiter in Indonesia per ridurre i costi e ha recentemente acquisito un nuovo cliente MSO sulla costa Est come partner esclusivo per hardware da vape.
Nonostante le prestazioni complessive inferiori, l'azienda ha mantenuto una posizione di cassa stabile a 4,3 milioni di dollari e ha migliorato il flusso di cassa operativo a 1,9 milioni di dollari rispetto a -2,4 milioni dell'anno precedente.
La empresa está ejecutando una transformación estratégica para convertirse en un negocio centrado en Jupiter, deshaciéndose de activos relacionados con la planta. Entre los desarrollos clave se incluye la firma de un acuerdo de 2 millones de dólares para vender dos dispensarios en Massachusetts y la obtención de la certificación de dispositivo médico de la UE para el vaporizador QMID de Jupiter. TILT está trasladando la producción de Jupiter a Indonesia para reducir costos y recientemente añadió un nuevo cliente MSO en la Costa Este como socio exclusivo para hardware de vapeo.
A pesar del menor rendimiento general, la compañía mantuvo posiciones de efectivo estables en 4,3 millones de dólares y mejoró el flujo de caja operativo a 1,9 millones de dólares en comparación con -2,4 millones del año anterior.
회사는 식물 관련 자산을 매각하여 주피터 중심 사업으로 전략적 전환을 진행 중입니다. 주요 내용으로는 매사추세츠 내 두 개의 디스펜서리 매각을 위한 200만 달러 계약 체결과 주피터 QMID 베이퍼라이저의 EU 의료기기 인증 획득이 포함됩니다. 또한, 비용 절감을 위해 주피터 생산을 인도네시아로 이전 중이며, 최근 동부 해안의 새로운 MSO 고객을 독점 베이프 하드웨어 파트너로 확보했습니다.
전반적인 실적은 하락했지만, 회사는 430만 달러의 안정적인 현금 보유고를 유지했으며, 영업 현금 흐름은 전년도의 -240만 달러에서 190만 달러로 개선되었습니다.
L'entreprise met en œuvre une transformation stratégique pour devenir une société axée sur Jupiter en se séparant des actifs liés à la culture. Parmi les développements clés, la signature d'un contrat de 2 M$ pour la vente de deux dispensaires dans le Massachusetts et l'obtention de la certification européenne pour le dispositif médical du vaporisateur QMID de Jupiter. TILT déplace la production de Jupiter en Indonésie pour réduire les coûts et a récemment ajouté un nouveau client MSO sur la côte Est en tant que partenaire exclusif pour le matériel de vape.
Malgré une performance globale moindre, la société a maintenu une trésorerie stable à 4,3 M$ et amélioré son flux de trésorerie d'exploitation à 1,9 M$ contre -2,4 M$ l'année précédente.
Das Unternehmen führt eine strategische Transformation durch, um ein Jupiter-fokussiertes Geschäft zu werden, indem es pflanzenbezogene Vermögenswerte veräußert. Wichtige Entwicklungen umfassen den Abschluss eines 2-Millionen-Dollar-Vertrags zum Verkauf von zwei Apotheken in Massachusetts und die Erlangung der EU-Medizinproduktezertifizierung für den QMID-Verdampfer von Jupiter. TILT verlagert die Jupiter-Produktion nach Indonesien, um Kosten zu senken, und hat kürzlich einen neuen MSO-Kunden an der Ostküste als exklusiven Partner für Vape-Hardware gewonnen.
Trotz der insgesamt geringeren Leistung behielt das Unternehmen stabile Barbestände von 4,3 Mio. USD bei und verbesserte den operativen Cashflow auf 1,9 Mio. USD gegenüber -2,4 Mio. USD im Vorjahr.
- Secured EU medical device certification for Jupiter's QMID vaporizer, expanding market opportunities
- Added new East Coast MSO customer as exclusive Jupiter vape hardware partner
- Improved operating cash flow to $1.9M from -$2.4M year-over-year
- Strategic production shift to Indonesia to reduce tariffs and costs
- Signed $2M agreement to sell Massachusetts dispensaries, advancing asset-light strategy
- Revenue declined 39.5% to $22.7M from $37.5M year-over-year
- Net loss widened to $13.2M from $9.7M in prior year
- Gross margin decreased to 14.9% from 17.9% year-over-year
- Adjusted EBITDA turned negative at $(974)K compared to positive $38K last year
PHOENIX, May 15, 2025 (GLOBE NEWSWIRE) -- TILT Holdings Inc. (“TILT” or the “Company”) (Cboe CA: TILT) (OTCPK: TLLTF), a global provider of cannabis business solutions including inhalation technologies, cultivation, manufacturing, processing, brand development and retail, is reporting its financial and operating results for the three months ended March 31, 2025. All financial information is reported in U.S. dollars and prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) unless otherwise indicated.
“This quarter marked an important step forward in reshaping TILT into a streamlined, Jupiter-first business as we continued to take decisive action to simplify operations and sharpen our strategic focus,” said TILT’s Chief Executive Officer, Tim Conder. “We are executing our plan to divest plant-touching assets with the announced definitive agreement to sell two Massachusetts retail stores and activity underway for our other plant touching businesses, which we believe will ultimately enable a more durable and scalable asset-light operating model. Once completed, this shift will allow us to fully realize Jupiter’s potential by expanding into new markets and strengthening our access to capital, ultimately driving sustainable growth, margin improvement, and consistent cash flow generation.
“At Jupiter, we’re excited to see steady demand for our innovative products, including the recent EU medical device certification – a first for handheld liquid vaporizers, marking a new era of innovation in medical cannabis delivery and paving the way for improved patient care. In addition, at Jupiter, we have begun augmenting our portfolio for customers that require product diversification and will be focused on technology development for the future.”
Conder added, “Although our transformation is still underway, we are making measurable progress to reposition the Company. Our ability to navigate a challenging market environment has been instrumental to this evolution. As we look ahead, we remain confident that Jupiter’s innovation and trustworthy, customer-centric approach will be a key driver of value in 2025 and beyond.”
Q1 2025 Financial Summary
- Revenue was
$22.7 million in the three months ended March 31, 2025, compared to$37.5 million in the prior year period. The decrease in revenue was primarily driven by the Company’s Jupiter Hardware business, as expected. - Gross profit was
$3.4 million and gross margin was14.9% in the three months ended March 31, 2025, compared to$6.7 million or17.9% of revenue in the prior year period. The decrease in gross margin was driven by lower margins in the Company’s plant-touching operations, which offset the improvement in Jupiter gross margin resulting from its transition to a commission-based structure. Adjusted gross margin, which excludes non-cash inventory adjustments and one-time adjustments, in the first quarter was18% compared to16% in the year-ago period. - Net loss was
$13.2 million in the three months ended March 31, 2025, compared to a net loss of$9.7 million in the prior year period. - Adjusted EBITDA (non-GAAP) was
$(974) thousand in the three months ended March 31, 2025, compared to$38 thousand in the prior year period driven by the aforementioned lower revenue and consolidated gross margin. - Cash flow provided from operating activities in the first quarter was
$1.9 million compared to cash used of$2.4 million in the year-ago period. - At March 31, 2025, the Company had
$4.3 million of cash, cash equivalents and restricted cash, which was flat compared to December 31, 2024.
Q1 2025 & Recent Operational Highlights
- Announced a definitive agreement to sell two Massachusetts dispensaries to In Good Health for
$2 million , including a cultivation supply agreement. - Subsequent to quarter end, the Company added a new East Coast MSO customer to become an exclusive Jupiter vape hardware partner.
- Achieved first-ever European Union medical device certification for Jupiter’s proprietary QMID handheld liquid vaporizer device, which is being brought to market in partnership with Curaleaf across the UK, Canada, Australia and New Zealand.
- Continued shifting Jupiter production to Indonesia to mitigate tariffs and reduce trade-related cost exposure.
Earnings Call and Webcast
TILT management will host a conference call today at 5:00 p.m. Eastern time to discuss its financial and operational results, business strategy and future outlook.
Date: Thursday, May 15th, 2025
Time: 5:00 p.m. Eastern Time
Toll-free dial-in number: (877) 423-9813
International dial-in number: (201) 689-8573
Webcast: TILT Q1 2025 Earnings Call
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Elevate IR at (720) 330-2829.
The conference call will also be available for replay in the investor relations section of the Company’s website at www.tiltholdings.com.
About TILT
TILT Holdings manages a diverse portfolio of companies in the cannabis industry, encompassing technology, hardware, cultivation, and production. Its core business, Jupiter Research LLC, is a wholly owned subsidiary and a global distribution leader in the vaporization segment. Jupiter is dedicated to hardware design, research, development, and distribution to support cannabis brands and retailers across the United States, Canada, South America, and the European Union. Additionally, TILT is a multi-state operator, with cultivation and production facilities in three states under the Commonwealth Alternative Care and Standard Farms brands. For more information, visit www.tiltholdings.com.
Forward-Looking Information
This news release contains forward-looking information and statements (together, “forward-looking information”) under applicable Canadian and U.S. securities laws which are based on current expectations. Forward-looking information is provided for the purpose of presenting information about TILT management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information may include, without limitation, outcome of the Company’s strategic review of plant touching assets, expected completion and timeline of divestitures of plant-touching assets, increased focus and growth of Jupiter in relation to any potential divestiture of the plant touching assets, strengthening of TILT’s balance sheet, TILT’s expectations on reductions in corporate overhead and headcount and re-alignment of its business, TILT’s business strategy and growth opportunities, Jupiter’s innovation and customer centric approach as a key driver of value, the opinions or beliefs of management, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies, and outlook of TILT, and includes statements about, among other things, future developments, the future operations, strengths and strategy of TILT. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “will”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. These statements should not be read as guarantees of future performance or results. These statements are based upon certain material factors, assumptions and analyses that were applied in drawing a conclusion or making a forecast or projection, including TILT’s experience and perceptions of historical trends, the ability of TILT to maximize shareholder value, current conditions and expected future developments, as well as other factors that are believed to be reasonable in the circumstances.
Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on forward-looking information. TILT assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.
By its nature, forward-looking information is subject to risks and uncertainties, and there are a variety of risk factors, many of which are beyond the control of TILT, and that may cause actual outcomes to differ materially from those discussed in the forward-looking information. Such risk factors include, but are not limited to, TILT’s ability to find a permanent successor executive, the impact of the announcement of the leadership change on TILT’s stock, performance, operations, results of operations, employees, suppliers and customers, TILT’s ability to successfully work through the leadership transition, TILT’s ability to execute on its business optimization strategy, capital preservation and cash generation, and reductions in corporate overhead and headcount and re-alignment of its business and those risks described under the heading “Item 1A Risk Factors” in the Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other subsequent reports filed by TILT with the United States Securities and Exchange Commission at www.sec.gov and on SEDAR+ at www.sedarplus.ca.
Non-GAAP Financial and Performance Measures
In addition to providing financial measurements based on GAAP, the Company provides additional financial metrics that are not prepared in accordance with GAAP. Management uses non-GAAP financial measures, in addition to GAAP financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes and to evaluate the Company’s financial performance. These non-GAAP financial measures are Adjusted Gross Margin, Adjusted Net Income (Loss), EBITDA and Adjusted EBITDA. Management believes that these non-GAAP financial measures reflect the Company’s ongoing business in a manner that allows for meaningful comparisons and analysis of trends in the business, as they facilitate comparing financial results across accounting periods and to those of peer companies. Management also believes that these non-GAAP financial measures enable investors to evaluate the Company’s operating results and future prospects in the same manner as management. These non-GAAP financial measures may also exclude expenses and gains that may be unusual in nature, infrequent or not reflective of the Company’s ongoing operating results.
As there are no standardized methods of calculating these non-GAAP measures, the Company’s methods may differ from those used by others, and accordingly, the use of these measures may not be directly comparable to similarly titled measures used by others.
Accordingly, these non-GAAP measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP.
Adjusted Gross Profit, Adjusted Gross Margin, EBITDA and Adjusted EBITDA.
Adjusted Gross Profit, Adjusted Gross Margin, EBITDA and Adjusted EBITDA are financial measures that are not defined under GAAP. The Company uses these non-GAAP financial measures, and believes they enhance an investor’s understanding of the Company’s financial and operating performance from period to period, because they exclude certain material non-cash items and certain other adjustments management believes are not reflective of the Company’s ongoing operations and performance. The Company calculates Adjusted Gross Profit as Gross Profit plus non-cash inventory adjustments, plus (minus) one-time adjustments. The Company calculates Adjusted Gross Margin as Adjusted Gross Profit divided by revenue. EBITDA is calculated as EBITDA net income (loss), plus (minus) income taxes (recovery), plus (minus) finance expense (income), plus depreciation and amortization expense. Adjusted EBITDA is EBITDA excluding certain one-time, non-cash or non-operating expenses, as determined by management, including stock compensation expense, debt issuance costs and severance.
Company Contact:
Lynn Ricci, VP of Investor Relations & Corporate Communications
TILT Holdings Inc.
lricci@tiltholdings.com
Investor Relations Contact:
Sean Mansouri, CFA
Elevate IR
TILT@elevate-ir.com
720.330.2829
| Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) | |||||||||||
| (Amounts Expressed in Thousands of United States Dollars) | |||||||||||
| Three Months Ended | |||||||||||
| March 31, | December 31, | March 31, | |||||||||
| 2025 | 2024 | 2024 | |||||||||
| Revenues, net | $ | 22,725 | $ | 24,562 | $ | 37,504 | |||||
| Cost of goods sold | (19,333 | ) | (19,280 | ) | (30,787 | ) | |||||
| Gross profit | 3,392 | 5,282 | 6,717 | ||||||||
| Operating expenses: | |||||||||||
| Wages and benefits | 3,872 | 4,118 | 4,496 | ||||||||
| General and administrative | 3,346 | 3,074 | 3,483 | ||||||||
| Sales and marketing | 58 | 124 | 142 | ||||||||
| Share-based compensation | 65 | (178 | ) | 107 | |||||||
| Depreciation and amortization | 2,620 | 3,855 | 3,866 | ||||||||
| Impairment loss and loss on disposal of assets | — | 27,353 | 12 | ||||||||
| Total operating expenses | 9,961 | 38,346 | 12,106 | ||||||||
| Operating loss | (6,569 | ) | (33,064 | ) | (5,389 | ) | |||||
| Other (expense) income: | |||||||||||
| Interest income | — | 1 | 2 | ||||||||
| Other income | 1,034 | 55 | 204 | ||||||||
| Gain (loss) on sale of assets and membership interests | — | — | — | ||||||||
| Unrealized loss on investment | — | — | (1 | ) | |||||||
| Loan receivable losses | — | — | — | ||||||||
| Gain (loss) on foreign currency exchange | 2 | — | (4 | ) | |||||||
| Interest expense | (7,563 | ) | (6,870 | ) | (6,043 | ) | |||||
| Total other (expense) income | (6,527 | ) | (6,814 | ) | (5,842 | ) | |||||
| Loss from operations before income tax and non-controlling interest | (13,096 | ) | (39,878 | ) | (11,231 | ) | |||||
| Income taxes | |||||||||||
| Income tax (expense) benefit | (144 | ) | (1,545 | ) | 1,580 | ||||||
| Net loss before non-controlling interest | (13,240 | ) | (41,423 | ) | (9,651 | ) | |||||
| Less: Net income attributable to non-controlling interest | — | — | — | ||||||||
| Net loss attributable to TILT Holdings Inc. | $ | (13,240 | ) | $ | (41,423 | ) | $ | (9,651 | ) | ||
| Reconcilation of Non-GAAP Measures (Unaudited) | |||||||||||
| (Amounts Expressed in Thousands of United States Dollars) | |||||||||||
| Three Months Ended | |||||||||||
| March 31, 2025 | December 31, 2024 | March 31, 2024 | |||||||||
| Net (loss) income before non-controlling interest | $ | (13,240 | ) | $ | (41,423 | ) | $ | (9,651 | ) | ||
| Add (deduct) impact of: | |||||||||||
| Interest income | — | (1 | ) | (2 | ) | ||||||
| Interest expense | 7,563 | 6,870 | 6,043 | ||||||||
| Income tax expense (benefit) | 144 | 1,545 | (1,580 | ) | |||||||
| Depreciation and amortization | 4,099 | 5,342 | 5,684 | ||||||||
| Total adjustments | 11,806 | 13,756 | 10,145 | ||||||||
| EBITDA (Non-GAAP) | $ | (1,434 | ) | $ | (27,667 | ) | $ | 494 | |||
| Add (deduct) impact of: | |||||||||||
| Share-based compensation | 65 | (178 | ) | 107 | |||||||
| Severance | 86 | 404 | 13 | ||||||||
| (Gain) loss on sale of assets | — | — | — | ||||||||
| Legal settlement | — | 105 | — | ||||||||
| Unrealized loss on investment in equity security | — | — | 1 | ||||||||
| Loss on loan receivable | — | — | — | ||||||||
| Impairment loss and loss on disposal of assets | — | 27,353 | 12 | ||||||||
| Foreign exchange (gain) Loss | — | — | 4 | ||||||||
| Non-cash inventory adjustment | 775 | 526 | 13 | ||||||||
| One time bad debt expense | — | — | — | ||||||||
| One time adjustments | (466 | ) | — | (606 | ) | ||||||
| Total adjustments | 460 | 28,210 | (456 | ) | |||||||
| Adjusted EBITDA (Non-GAAP) | (974 | ) | 543 | 38 | |||||||
| Net loss before non-controlling interest | (13,240 | ) | (41,423 | ) | (9,651 | ) | |||||
| Add (deduct) impact of: | |||||||||||
| Impairment loss and loss on disposal of assets | — | 27,353 | 12 | ||||||||
| Adjusted net loss before non-controlling interest | (13,240 | ) | (14,070 | ) | (9,639 | ) | |||||
| Condensed Consolidated Statements of Cash Flows (Unaudited) | |||||||
| (Amounts Expressed in Thousands of United States Dollars) | |||||||
| Three Months Ended | |||||||
| March 31, 2025 | March 31, 2024 | ||||||
| Net cash provided by (used in) operating activities | $ | 1,903 | $ | (2,439 | ) | ||
| Net cash (used in) provided by investing activities | (2,089 | ) | (185 | ) | |||
| Net cash provided by (used in) financing activities | 219 | 2,819 | |||||
| Effect of foreign exchange on cash and cash equivalents | - | (8 | ) | ||||
| Net change in cash and cash equivalents | 33 | 187 | |||||
| Cash and cash equivalents and restricted cash, beginning of period | 4,303 | 3,332 | |||||
| Cash and cash equivalents and restricted cash, end of period | $ | 4,336 | $ | 3,519 | |||
| Condensed Consolidated Balance Sheets (Select Items) | |||||||
| (Amounts Expressed in Thousands of United States Dollars) | |||||||
| Periods Ended | |||||||
| March 31, 2025 | December 31, 2024 | ||||||
| (unaudited) | (audited) | ||||||
| Cash and cash equivalents | $ | 3,036 | $ | 3,003 | |||
| Restricted cash | 1,300 | 1,300 | |||||
| Trade receivables and others | 12,470 | 11,904 | |||||
| Inventories | 18,924 | 22,505 | |||||
| Total current assets | 38,444 | 40,847 | |||||
| Property, plant & equipment, net | 30,371 | 30,733 | |||||
| Total assets | 149,737 | 151,324 | |||||
| Total current liabilities | 124,394 | 87,455 | |||||
| Total long-term liabilities | 75,720 | 101,071 | |||||
| Total shareholders’ equity | (50,377 | ) | (37,202 | ) | |||
| Reconcilation of Non-GAAP Measures for Gross Profit | |||||||||||
| (Amounts Expressed in Thousands of United States Dollars) | |||||||||||
| Three Months Ended | |||||||||||
| March 31, | December 31, | March 31, | |||||||||
| 2025 | 2024 | 2024 | |||||||||
| Revenues, net | $ | 22,725 | $ | 24,562 | $ | 37,504 | |||||
| Cost of goods sold | (19,333 | ) | (19,280 | ) | (30,787 | ) | |||||
| Gross profit $ | 3,392 | 5,282 | 6,717 | ||||||||
| Gross profit % | 14.9 | % | 21.5 | % | 17.9 | % | |||||
| Add (deduct) impact of: | |||||||||||
| One-time adjustment* | — | — | (717 | ) | |||||||
| Non-cash inventory adjustment | 775 | 526 | 13 | ||||||||
| Total adjustments | 775 | 526 | (704 | ) | |||||||
| Adjusted gross profit $ (Non-GAAP) | 4,167 | 5,808 | 6,013 | ||||||||
| Adjusted gross profit % (Non-GAAP) | 18.3 | % | 23.6 | % | 16.0 | % | |||||
| * One-time adjustment related to Taunton's Host Fee Reversal | |||||||||||
FAQ
What were TILT Holdings (TLLTF) Q1 2025 earnings results?
Why is TILT Holdings selling its Massachusetts dispensaries?
What is significant about TILT's Jupiter QMID vaporizer certification?
How much cash does TILT Holdings have as of Q1 2025?
What strategic changes is TILT implementing to improve performance?
